Literature DB >> 29737433

Report of a bi-allelic truncating germline mutation in TP53.

Natasha J Brown1,2,3, Kanika Bhatia4, Julie Teague5, Susan M White6,7,8, Patrick Lo9, Jackie Challis6, Victoria Beshay10, Michael Sullivan4, David Malkin11, Jordan R Hansford7,4,8.   

Abstract

The TP53 gene is fundamental to genomic integrity, cell cycle regulation, and apoptosis; it is the most commonly mutated gene in human cancer. Heterozygous germline mutations cause the autosomal dominant cancer predisposition syndrome, Li-Fraumeni Syndrome. Homozygous germline TP53 mutations in humans are rare. We report an infant from a consanguineous family who presented with synchronous malignancies. Remarkably, he carries a homozygous germline TP53 mutation (NM_000546.4:c.52delA), predicted to cause protein truncation. The family history is consistent with Li-Fraumeni syndrome.

Entities:  

Keywords:  Homozygous germline; Li-Fraumeni syndrome; Pediatric oncology; TP53

Mesh:

Substances:

Year:  2019        PMID: 29737433     DOI: 10.1007/s10689-018-0087-1

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  10 in total

1.  Transmission of germline TP53 mutations from male carriers to female partners.

Authors:  Sophie Patrier-Sallebert; Gaëlle Bougeard; Stéphanie Baert-Desurmont; Aude Lamy; Jean-Michel Flaman; Ludovic Mansuy; Myriam Bronner; Christine Lasset; Laurence Brugières; François Golfier; Thierry Frebourg
Journal:  J Med Genet       Date:  2015-01-22       Impact factor: 6.318

2.  TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.

Authors:  Liacine Bouaoun; Dmitriy Sonkin; Maude Ardin; Monica Hollstein; Graham Byrnes; Jiri Zavadil; Magali Olivier
Journal:  Hum Mutat       Date:  2016-07-08       Impact factor: 4.878

3.  p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.

Authors:  S Quesnel; S Verselis; C Portwine; J Garber; M White; J Feunteun; D Malkin; F P Li
Journal:  Oncogene       Date:  1999-07-08       Impact factor: 9.867

4.  Gestational choriocarcinoma associated with a germline TP53 mutation.

Authors:  Anne-Claire Brehin; Sophie Patrier-Sallebert; Gaëlle Bougeard; Gwendoline Side-Pfennig; Francisco Llamas Gutierrez; Aude Lamy; Elodie Colasse; Christine Kandel-Aznar; Capucine Delnatte; Eric Vuillemin; Sophie Sadot-Lebouvier; Sylvie Odent; Jean-Christophe Sabourin; François Golfier; Thierry Frebourg
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

5.  An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors.

Authors:  A C Latronico; E M Pinto; S Domenice; M C Fragoso; R M Martin; M C Zerbini; A M Lucon; B B Mendonca
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

6.  Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.

Authors:  Gislaine Custódio; Guilherme A Parise; Nilton Kiesel Filho; Heloisa Komechen; Cesar C Sabbaga; Roberto Rosati; Leila Grisa; Ivy Z S Parise; Mara A D Pianovski; Carmem M C M Fiori; Jorge A Ledesma; José Renato S Barbosa; Francisco R O Figueiredo; Elis R Sade; Humberto Ibañez; Sohaila B I Arram; Sérvio T Stinghen; Luciano R Mengarelli; Mirna M O Figueiredo; Danilo C Carvalho; Sylvio G A Avilla; Thiago D Woiski; Lisiane C Poncio; Geneci F R Lima; Roberto Pontarolo; Enzo Lalli; Yinmei Zhou; Gerard P Zambetti; Raul C Ribeiro; Bonald C Figueiredo
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

7.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals.

Authors:  A Chompret; L Brugières; M Ronsin; M Gardes; F Dessarps-Freichey; A Abel; D Hua; L Ligot; M G Dondon; B Bressac-de Paillerets; T Frébourg; J Lemerle; C Bonaïti-Pellié; J Feunteun
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

8.  ClinVar: improving access to variant interpretations and supporting evidence.

Authors:  Melissa J Landrum; Jennifer M Lee; Mark Benson; Garth R Brown; Chen Chao; Shanmuga Chitipiralla; Baoshan Gu; Jennifer Hart; Douglas Hoffman; Wonhee Jang; Karen Karapetyan; Kenneth Katz; Chunlei Liu; Zenith Maddipatla; Adriana Malheiro; Kurt McDaniel; Michael Ovetsky; George Riley; George Zhou; J Bradley Holmes; Brandi L Kattman; Donna R Maglott
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

9.  TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.

Authors:  Juliana Giacomazzi; Simone Selistre; Juliana Duarte; Jorge Pinto Ribeiro; Paulo J C Vieira; Gabriel de Souza Macedo; Cristina Rossi; Mauro Czepielewski; Cristina Brinkmann Oliveira Netto; Pierre Hainaut; Patricia Ashton-Prolla
Journal:  BMC Cancer       Date:  2013-04-09       Impact factor: 4.430

Review 10.  Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner.

Authors:  Jennifer A Cotter; Linda Szymanski; Catherine Karimov; Lara Boghossian; Ashley Margol; Girish Dhall; Benita Tamrazi; G Isaac Varaprasathan; David M Parham; Alexander R Judkins; Jaclyn A Biegel
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.